<DOC>
	<DOCNO>NCT01922154</DOCNO>
	<brief_summary>To evaluate effect intravitreal ranibizumab ( IVR ) adjunctive treatment trabeculectomy mitomycin C ( TMC ) neovascular glaucoma ( NVG ) .</brief_summary>
	<brief_title>Intravitreous Ranibizumab Adjunctive Treatment Trabeculectomy Neovascular Glaucoma</brief_title>
	<detailed_description>This prospective study 15 consecutive eye 14 patient ( One patient NVG eye presentation . ) NVG present Department Ophthalmology , Faculty Medicine Siriraj Hospital , Mahidol University , Bangkok , Thailand December 2008 December 2009 . Each eye receive IVR ( 0.5 mg/0.05 ml ) 1 week TMC . Trabeculectomy perform fornix-based conjunctival flap method .</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Neovascular</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Consecutive patient neovascular glaucoma Age 80 year old Provide write informed consent Uncooperated patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Angiogenesis inhibitor</keyword>
	<keyword>Neovascular</keyword>
	<keyword>Intraocular pressure</keyword>
	<keyword>Retinal Vein Occlusion</keyword>
	<keyword>Vascular Endothelial Growth Factor</keyword>
</DOC>